AORT Stock Up 39% after 7-Day Win Streak
Artivion (AORT) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 39% return. The company has gained about $742 Mil in value over the last 7 days, with its current market capitalization at about $1.9 Bil. The stock remains 50.3% above its value at the end of 2024. This compares with year-to-date returns of 8.4% for the S&P 500.
AORT manufactures and distributes medical devices and implantable tissues, including BioGlue adhesive and E-xtra engineering systems for treating aortic vascular diseases worldwide. After this rally, is AORT still a buy – or is it time to lock in gains? Deep dive with Buy or Sell AORT.
Comparing AORT Stock Returns With The S&P 500
The following table summarizes the return for AORT stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | AORT | S&P 500 |
|---|---|---|
| 1D | 4.9% | -0.3% |
| 7D (Current Streak) | 39.0% | 0.5% |
| 1M (21D) | 36.6% | 1.8% |
| 3M (63D) | 48.6% | 12.6% |
| YTD 2025 | 50.3% | 8.4% |
| 2024 | 59.9% | 23.3% |
| 2023 | 47.5% | 24.2% |
| 2022 | -40.4% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has AORT behaved after prior drops? See AORT Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 49 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 37 |
| 4D | 11 | 14 |
| 5D | 1 | 9 |
| 6D | 8 | 0 |
| 7D or more | 2 | 2 |
| Total >=3 D | 49 | 62 |
Key Financials for Artivion (AORT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $354.0 Mil | $388.5 Mil |
| Operating Income | $-8.5 Mil | $38.9 Mil |
| Net Income | $-30.7 Mil | $-13.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $99.0 Mil | $113.0 Mil |
| Operating Income | $2.1 Mil | $8.4 Mil |
| Net Income | $-0.5 Mil | $1.3 Mil |
While AORT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.